Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy

Sharon Dudley-Brown, Arpita Nag, Cory Cullinan, Mary Ayers, Steve Hass, Sumeet Panjabi

Research output: Contribution to journalArticle

Abstract

Crohn disease (CD) is a chronic inflammatory condition without a permanent medical cure and commonly requiring a lifetime of care. This article discusses the impact of natalizumab induction and maintenance therapy on the health-related quality of life (HRQoL) of CD patients. Two natalizumab phase III studies were evaluated: the Efficacy of Natalizumab in Crohns Disease Response and Remission (ENCORE) study evaluated the HRQoL of CD patients during 12 weeks of natalizumab induction therapy, and the Evaluation of Natalizumab As Continuous Therapy (ENACT-2) trial evaluated the effect of natalizumab maintenance therapy on HRQoL for a period of 48 weeks past a 12-week induction period (ENACT-1). HRQoL assessments were made with the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36). In the ENCORE study, induction therapy with natalizumab was demonstrated to significantly increase HRQoL scores at 12 weeks when compared with patients on placebo. During the ENACT-2 trial, IBDQ and SF-36 scale scores of patients who responded to natalizumab induction remained stable whereas those on placebo worsened. At week 60, the mean change from baseline on all scales of the IBDQ and the SF-36 were significantly higher for those who continued to receive natalizumab as compared to those who received placebo (p ≤ .016 for all scales). Natalizumab significantly improved the patient's clinical status and HRQoL shortly after treatment was initiated, and the effect was maintained for 60 weeks.

Original languageEnglish (US)
Pages (from-to)327-339
Number of pages13
JournalGastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates
Volume32
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Crohn Disease
Quality of Life
Inflammatory Bowel Diseases
Therapeutics
Placebos
Natalizumab

ASJC Scopus subject areas

  • Advanced and Specialized Nursing
  • Gastroenterology
  • Medicine(all)

Cite this

Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. / Dudley-Brown, Sharon; Nag, Arpita; Cullinan, Cory; Ayers, Mary; Hass, Steve; Panjabi, Sumeet.

In: Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates, Vol. 32, No. 5, 09.2009, p. 327-339.

Research output: Contribution to journalArticle

@article{64b46122e6e84e129869fe06a8a340c3,
title = "Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy",
abstract = "Crohn disease (CD) is a chronic inflammatory condition without a permanent medical cure and commonly requiring a lifetime of care. This article discusses the impact of natalizumab induction and maintenance therapy on the health-related quality of life (HRQoL) of CD patients. Two natalizumab phase III studies were evaluated: the Efficacy of Natalizumab in Crohns Disease Response and Remission (ENCORE) study evaluated the HRQoL of CD patients during 12 weeks of natalizumab induction therapy, and the Evaluation of Natalizumab As Continuous Therapy (ENACT-2) trial evaluated the effect of natalizumab maintenance therapy on HRQoL for a period of 48 weeks past a 12-week induction period (ENACT-1). HRQoL assessments were made with the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36). In the ENCORE study, induction therapy with natalizumab was demonstrated to significantly increase HRQoL scores at 12 weeks when compared with patients on placebo. During the ENACT-2 trial, IBDQ and SF-36 scale scores of patients who responded to natalizumab induction remained stable whereas those on placebo worsened. At week 60, the mean change from baseline on all scales of the IBDQ and the SF-36 were significantly higher for those who continued to receive natalizumab as compared to those who received placebo (p ≤ .016 for all scales). Natalizumab significantly improved the patient's clinical status and HRQoL shortly after treatment was initiated, and the effect was maintained for 60 weeks.",
author = "Sharon Dudley-Brown and Arpita Nag and Cory Cullinan and Mary Ayers and Steve Hass and Sumeet Panjabi",
year = "2009",
month = "9",
doi = "10.1097/SGA.0b013e3181bb1484",
language = "English (US)",
volume = "32",
pages = "327--339",
journal = "Gastroenterology Nursing",
issn = "1042-895X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy

AU - Dudley-Brown, Sharon

AU - Nag, Arpita

AU - Cullinan, Cory

AU - Ayers, Mary

AU - Hass, Steve

AU - Panjabi, Sumeet

PY - 2009/9

Y1 - 2009/9

N2 - Crohn disease (CD) is a chronic inflammatory condition without a permanent medical cure and commonly requiring a lifetime of care. This article discusses the impact of natalizumab induction and maintenance therapy on the health-related quality of life (HRQoL) of CD patients. Two natalizumab phase III studies were evaluated: the Efficacy of Natalizumab in Crohns Disease Response and Remission (ENCORE) study evaluated the HRQoL of CD patients during 12 weeks of natalizumab induction therapy, and the Evaluation of Natalizumab As Continuous Therapy (ENACT-2) trial evaluated the effect of natalizumab maintenance therapy on HRQoL for a period of 48 weeks past a 12-week induction period (ENACT-1). HRQoL assessments were made with the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36). In the ENCORE study, induction therapy with natalizumab was demonstrated to significantly increase HRQoL scores at 12 weeks when compared with patients on placebo. During the ENACT-2 trial, IBDQ and SF-36 scale scores of patients who responded to natalizumab induction remained stable whereas those on placebo worsened. At week 60, the mean change from baseline on all scales of the IBDQ and the SF-36 were significantly higher for those who continued to receive natalizumab as compared to those who received placebo (p ≤ .016 for all scales). Natalizumab significantly improved the patient's clinical status and HRQoL shortly after treatment was initiated, and the effect was maintained for 60 weeks.

AB - Crohn disease (CD) is a chronic inflammatory condition without a permanent medical cure and commonly requiring a lifetime of care. This article discusses the impact of natalizumab induction and maintenance therapy on the health-related quality of life (HRQoL) of CD patients. Two natalizumab phase III studies were evaluated: the Efficacy of Natalizumab in Crohns Disease Response and Remission (ENCORE) study evaluated the HRQoL of CD patients during 12 weeks of natalizumab induction therapy, and the Evaluation of Natalizumab As Continuous Therapy (ENACT-2) trial evaluated the effect of natalizumab maintenance therapy on HRQoL for a period of 48 weeks past a 12-week induction period (ENACT-1). HRQoL assessments were made with the Inflammatory Bowel Disease Questionnaire (IBDQ) and the Short Form-36 (SF-36). In the ENCORE study, induction therapy with natalizumab was demonstrated to significantly increase HRQoL scores at 12 weeks when compared with patients on placebo. During the ENACT-2 trial, IBDQ and SF-36 scale scores of patients who responded to natalizumab induction remained stable whereas those on placebo worsened. At week 60, the mean change from baseline on all scales of the IBDQ and the SF-36 were significantly higher for those who continued to receive natalizumab as compared to those who received placebo (p ≤ .016 for all scales). Natalizumab significantly improved the patient's clinical status and HRQoL shortly after treatment was initiated, and the effect was maintained for 60 weeks.

UR - http://www.scopus.com/inward/record.url?scp=70350346073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350346073&partnerID=8YFLogxK

U2 - 10.1097/SGA.0b013e3181bb1484

DO - 10.1097/SGA.0b013e3181bb1484

M3 - Article

C2 - 19820441

AN - SCOPUS:70350346073

VL - 32

SP - 327

EP - 339

JO - Gastroenterology Nursing

JF - Gastroenterology Nursing

SN - 1042-895X

IS - 5

ER -